Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Hemorrhage 2 Thrombocytopenia 1 Recurrence 1 Postoperative Hemorrhage 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Melanoma 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1 Colonic Neoplasms 1 Breast Neoplasms 1 Brain Neoplasms 1 Blood Loss, Surgical 1

Interventions

pembrolizumab 54 Nivolumab 50 Ipilimumab 28 Cyclophosphamide 16 binimetinib 10 Specimen Handling 10 Magnetic Resonance Spectroscopy 10 fludarabine 9 Radiosurgery 9 relatlimab 8 encorafenib 8 Opdualag 8 Biopsy 8 aldesleukin 7 Interleukin-2 7 atezolizumab 6 Immunotherapy 6 Blood Specimen Collection 6 cemiplimab 5 CTLA-4 Antigen 5 Bevacizumab 5 trametinib 4 fludarabine phosphate 4 dabrafenib 4 Temozolomide 4 Paclitaxel 4 Immune Checkpoint Inhibitors 4 spartalizumab 3 Surgical Procedures, Operative 3 Metformin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Melanoma × Tranexamic Acid × Clear all

NCT05899465 2025-03-18

PRIME

University of Aarhus

Phase 3 Recruiting

Melanoma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡